|
ovarian neoplasm
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
|
21856257 |
2011 |
|
Malignant neoplasm of ovary
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
|
21856257 |
2011 |
|
Lung Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Here we identify the downstream of tyrosine kinase (Dok) family members Dok1, Dok2 and Dok3 as lung tumor suppressors.
|
20139980 |
2010 |
|
Malignant neoplasm of lung
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of DOK genes as lung tumor suppressors.
|
20139980 |
2010 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Docking protein-1 (DOK1) is a tumor suppressor frequently lost in malignant cells, however, it retains the ability to control activities of immune receptors in adjacent stroma cells of the tumor microenvironment.
|
31646096 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both NRIP1 and DOK1 genes are considered candidate tumor suppressor genes (TSGs).
|
28844109 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a large series of CRC patients, loss of DOK1 protein was associated with poor prognosis at early tumor stages (*p=0.001; n=1492).
|
27428427 |
2016 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Interestingly, DOK1 methylation levels in HCC samples were significantly higher in the group of younger (<40 years) patients, and higher in moderately differentiated than in poorly differentiated tumors (p < 0.05).
|
27078152 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these results suggest a novel mechanism of action of BRK in the promotion of tumor formation, which involves the targeting of tumor suppressor Dok1 for degradation through the ubiquitin proteasomal pathway.
|
24523872 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Epstein-Barr virus down-regulates tumor suppressor DOK1 expression.
|
24809689 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The PPARg-agonist rosiglitazone prevented tumor formation in mice irrespectively of the Cav1 status and upregulated expression of the Ras-inhibitory protein docking protein-1.
|
23640045 |
2013 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Control blood samples and exfoliated mouth epithelial cells from healthy individuals showed a low level of DOK1 methylation, suggesting that DOK1 hypermethylation is a tumour specific event.
|
21796618 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found a high frequency of aberrant hypermethylation of specific genes (RASSF1A, GSTP1, CHRNA3, and DOK1) in HCC tumors as compared to control cirrhotic or normal liver tissues, suggesting that aberrant hypermethylation exhibits non-random and tumor-specific patterns in HCC.
|
21146512 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our findings are suggestive for a possible tumor suppressor role of DOK1 in EOC; however its implication in enhanced EOC cell migration and proliferation restrain us to conclude that DOK1 represents a true TSG in EOC.
|
21856257 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dok1 is an adaptor tyrosine kinase substrate with tumor-suppressive activity.
|
16338067 |
2007 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Nck adaptors in interaction with Dok1 induce podosome biogenesis and ECM degradation facilitating cancer cell invasion, and therefore a bona fide target of cancer therapy.
|
31638742 |
2019 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
A total of 155 AML patients with DOK family (DOK1-7) expression data from The Cancer Genome Atlas database were enrolled in the study.
|
30348947 |
2019 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We have previously reported that DOK1 expression is up-regulated upon cellular stress, via the transcription factor E2F1, and down-regulated in a variety of human malignancies due to aberrant hypermethylation of its promoter.
|
24809689 |
2014 |
|
Malignant Neoplasms
|
0.060 |
PosttranslationalModification
|
group |
BEFREE |
We further observed that DOK1 hypermethylation occurs frequently in a variety of primary human neoplasm including solid tumours (93% in HNC, 81% in lung cancer) and haematopoietic malignancy (64% in Burkitt's lymphoma).
|
21796618 |
2012 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Among the genes identified, one of particular interest was DOK1, or downstream of tyrosine kinase 1, previously recognized as a candidate tumor suppressor gene (TSG) for leukemia and other human malignancies.
|
21856257 |
2011 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Our data show that Dok1 expression and structure are affected in a subset of Burkitt's lymphoma samples, suggesting its possible role in this type of cancer.
|
16338067 |
2007 |
|
leukemia
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Survival analyses showed that low-expressed DOK1/2 were associated with markedly shorter overall survival and leukemia free survival in both whole-cohort AML and non-M3 AML patients.
|
29150948 |
2018 |
|
leukemia
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
To assess the so far unknown role of DOK1 in colorectal cancer (CRC), we generated DOK1 mutants which mimic the domain structure and subcellular distribution of DOK1 protein variants in leukemia patients.
|
27428427 |
2016 |
|
leukemia
|
0.050 |
Biomarker
|
disease |
BEFREE |
The DOK1 gene is a putative tumour suppressor gene located on the human chromosome 2p13 which is frequently rearranged in leukaemia and other human tumours.
|
21796618 |
2012 |